NO GENERIC SUBSTITUTIONS AVAILABLE4
Low-alcohol formulation for
0.4% incidence of burning2*
Reservoir with active ingredient
remains 4 weeks after treatment5
Statistically significant cure rates
with
once-daily, 2-week dosing6
Proven effective and safe
fungicidal allylamine3
*NAFTIN GEL 2% has a lower incidence of burning sensation compared with NAFTIN GEL 1%
NAFTIN GEL 2% delivers the proven efficacy of an allylamine with a safety profile comparable to that of the vehicle.3,7
With the NAFTIN Co-Pay Program, $22 out-of-pocket costs for many eligible patients.8
NAFTIN GEL 2% is delivered deep through all layers of the stratum corneum5
INDICATIONS AND USAGE: NAFTIN GEL 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.
IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS: In clinical trials with NAFTIN GEL 2%, the most common adverse reactions (2%) were application site reactions.
WARNINGS AND PRECAUTIONS: If redness or irritation develops with the use of NAFTIN GEL 2%, treatment should be discontinued.
Please click here for full Prescribing Information about NAFTIN GEL 2%.
REFERENCES: 1. Vlahovic TC. Choosing the right vehicle. Podiatr Manage.
June/July 2008;209-214.
2. Data on file, Legacy Pharmaceuticals.
3. Naftin Gel 2%. Package insert. Legacy Pharmaceuticals; 2020.
4. Graybill JR, Burgess DS, Hardin TC. Key issues concerning fungistatic versus fungicidal drugs. Eur J Clin Microbiol Infect Dis. 1997;16(1):42-50.
5. Plaum S, Verma A, Fleischer AB, Olayinka B, Hardas B. Detection and relevance
of naftifine hydrochloride in the stratum corneum up to four weeks following the last application
of naftifine cream or gel 2%. J Drugs Dermatol. 2013;12(9):1004-1008.
6. Stein Gold L, Parish L, Vlahovic T, Kircik L, et al. Efficacy and safety of
naftifine HCL Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled
results from two multicenter, randomized, double-blind, vehicle-controlled trials.
J Drugs Dermatol. 2013;12(8):911-918.
7. Brennan B, Leyden JJ. Overview of topical therapy for common superficial
fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:S3-S8.
8. NAFTIN 2% Co-Pay Savings Offer. Legacy Pharmaceuticals, 2023.
9. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind,
vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis.
J Drugs Dermatol. November 2011;10(11):1282-1288.
10. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized,
vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris.
J Drugs Dermatol. October 2011;10(10):1142-1147.
11. Robbins CM, Elston DM. Tinea pedis treatment & management. Updated September 11, 2020. Accessed December 14, 2022. https://emedicine.medscape.com/article/1091684-treatment#showall
12. Phillips, RM, Rosen T. Topical antifungal agents. Allylamines and
benzylamines. In: Wolverton, SE, ed. Comprehensive Dermatologic Drug Therapy. 3rd ed.
Elsevier Inc. Ebook; 2013:460-472.
13. IQVIA. National Prescription Audit Report. October 2022.